Drug Profile
BP 14979
Alternative Names: BP 1.4979; BP1 4979Latest Information Update: 14 Mar 2022
Price :
$50
*
At a glance
- Originator Bioprojet
- Class Smoking cessation therapies
- Mechanism of Action Dopamine D3 receptor partial agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Binge-eating disorder; Restless legs syndrome; Smoking withdrawal
Most Recent Events
- 07 Mar 2022 Phase-II clinical trials in Binge-eating disorder in France (PO) in March 2022 (NCT05118906)
- 12 Nov 2021 Bioprojet plans a phase II trial for Binge-Eating Disorder(In adults) in December 2021(NCT05118906)
- 27 Sep 2021 Phase II development for Restless legs syndrome is still ongoing in France (Bioprojet's pipeline, September 2021) (NCT03345953)